Search

Your search keyword '"Zarbo, Ignazio Roberto"' showing total 35 results
Start Over Author "Zarbo, Ignazio Roberto"
35 results on '"Zarbo, Ignazio Roberto"'

2. The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)

Author

Bianchi, Alessia, Matranga, Domenica, Patti, Francesco, Maniscalco, Laura, Pilotto, Silvy, Di Filippo, Massimiliano, Zaffaroni, Mauro, Annovazzi, Pietro, Bertolotto, Antonio, Gasperini, Claudio, Quartuccio, Esmeralda, Centonze, Diego, Fantozzi, Roberta, Gajofatto, Alberto, Gobbin, Francesca, Landi, Doriana, Granella, Franco, Buccafusca, Maria, Marfia, Girolama Alessandra, Chisari, Clara, Naldi, Paola, Bergamaschi, Roberto, Greco, Giacomo, Zarbo, Ignazio Roberto, Rizzo, Vincenzo, Ulivelli, Monica, Bezzini, Daiana, Florio, Lucia, Turazzini, Michelangelo, Di Gregorio, Maria, Pugliatti, Maura, Salemi, Giuseppe, and Ragonese, Paolo

Published
2024
Full Text
View/download PDF

4. Identification of hsa_circ_0018905 as a New Potential Biomarker for Multiple Sclerosis.

Author

Lodde, Valeria, Zarbo, Ignazio Roberto, Farina, Gabriele, Masia, Aurora, Solla, Paolo, Campesi, Ilaria, Delogu, Giuseppe, Muroni, Maria Rosaria, Tsitsipatis, Dimitrios, Gorospe, Myriam, Floris, Matteo, and Idda, Maria Laura

Subjects
*DEMYELINATION, *GENE regulatory networks, *NON-coding RNA, *MULTIPLE sclerosis, *AUTOIMMUNE diseases, *CIRCULAR RNA
Abstract

Multiple sclerosis (MS) is a demyelinating autoimmune disease characterized by early onset, for which the interaction of genetic and environmental factors is crucial. Dysregulation of the immune system as well as myelinization-de-myelinization has been shown to correlate with changes in RNA, including non-coding RNAs. Recently, circular RNAs (circRNAs) have emerged as a key player in the complex network of gene dysregulation associated with MS. Despite several efforts, the mechanisms driving circRNA regulation and dysregulation in MS still need to be properly elucidated. Here, we explore the panorama of circRNA expression in PBMCs purified from five newly diagnosed MS patients and five healthy controls (HCs) using the Arraystar Human circRNAs microarray. Experimental validation was then carried out in a validation cohort, and a possible correlation with disease severity was tested. We identified 64 differentially expressed circRNAs, 53 of which were downregulated in PBMCs purified from MS compared to the HCs. The discovery dataset was subsequently validated using qRT-PCR with an independent cohort of 20 RRMS patients and 20 HCs. We validated seven circRNAs differentially expressed in the RRMS group versus the HC group. hsa_circ_0000518, hsa_circ_0000517, hsa_circ_0000514, and hsa_circ_0000511 were significantly upregulated in the MS group, while hsa_circ_0018905, hsa_circ_0048764, and hsa_circ_0003445 were significantly downregulated; Among them, the expression level of hsa_circ_0018905 was significantly decreased in patients showing a higher level of disability and in progressive forms of MS. We described the circRNAs expression profile of PBMCs in newly diagnosed MS patients and proposed hsa_circ_0018905 as potential MS biomarker. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Author

Sormani, Maria Pia, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri Rossi, Beatrice Maria, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Roberto, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, dʼAmbrosio, Alessandro, DʼAmico, Emanuele, Danni, Maura Chiara, dʼArma, Alessia, Dattola, Vincenzo, de Biase, Stefano, Luca, Giovanna De, Mercanti, Stefania Federica De, De Mitri, Paolo, De Stefano, Nicola, Cava, Marco Della, Napoli, Mario di, Sapio, Alessia Di, Docimo, Renato, Dutto, Anna, Evangelista, Luana, Fanara, Salvatore, Diana, Ferraro, Ferrò, Maria Teresa, Fioretti, Cristina, Fratta, Mario, Frau, Jessica, Fronza, Marzia, Furlan, Roberto, Gajofatto, Alberto, Gallo, Antonio, Gallo, Paolo, Gasperini, Claudio, Ghazaryan, Anna, Giometto, Bruno, Gobbin, Francesca, Govone, Flora, Granella, Franco, Grange, Erica, Grasso, Maria Grazia, Guareschi, Angelica, Guaschino, Clara, Guerrieri, Simone, Guidetti, Donata, Iaffaldano, Pietro, Ianniello, Antonio, Iasevoli, Luigi, Imperiale, Daniele, Infante, Maria Teresa, Iodice, Rosa, Iovino, Aniello, Konrad, Giovanna, Landi, Doriana, Lanzillo, Roberta, Lapucci, Caterina, Lavorgna, Luigi, LʼEpiscopo, Maria Rita, Leva, Serena, Liberatore, Giuseppe, Lo Re, Marianna, Longoni, Marco, Lopiano, Leonardo, Lorefice, Lorena, Lucchini, Matteo, Lus, Giacomo, Maimone, Davide, Malentacchi, Maria, Mallucci, Giulia, Malucchi, Simona, Mancinelli, Chiara Rosa, Mancinelli, Luca, Manganotti, Paolo, Maniscalco, Giorgia Teresa, Mantero, Vittorio, Marangoni, Sabrina, Marastoni, Damiano, Marinelli, Fabiana, Marti, Alessandro, Boneschi, Filippo Martinelli, Masserano Zoli, Federco, Matta, Francesca, Mendozzi, Laura, Meucci, Giuseppe, Miante, Silvia, Miele, Giuseppina, Milano, Eva, Mirabella, Massimiliano, Missione, Rosanna, Moccia, Marcello, Moiola, Lucia, Montepietra, Sara, MontiBragadin, Margherita, Montini, Federico, Motta, Roberta, Nardone, Raffaele, Nicoletti, Carolina Gabri, Nobile-Orazio, Eduardo, Nozzolillo, Agostino, Onofrj, Marco, Orlandi, Riccardo, Palmieri, Anna, Paolicelli, Damiano, Pasquali, Livia, Pastò, Luisa, Pedrazzoli, Elisabetta, Petracca, Maria, Petrone, Alfredo, Piantadosi, Carlo, Pietroboni, Anna M, Pinardi, Federica, Ponzano, Marta, Portaccio, Emilio, Pozzato, Mattia, Pozzilli, Carlo, Prosperini, Luca, Protti, Alessandra, Ragonese, Paolo, Rasia, Sarah, Realmuto, Sabrina, Repice, Anna, Rigoni, Eleonora, Rilla, Maria Teresa, Rinaldi, Francesca, Romano, Calogero Marcello, Ronzoni, Marco, Rovaris, Marco, Ruscica, Francesca, Sabattini, Loredana, Salemi, Giuseppe, Saraceno, Lorenzo, Sartori, Alessia, Sartori, Arianna, Sbragia, Elvira, Scarano, Giuditta Ilaria, Scarano, Valentina, Schillaci, Valentina, Sessa, Maria, Sgarito, Caterina, Sibilia, Grazia, Siciliano, Gabriele, Signori, Alessio, Signoriello, Elisabetta, Sinisi, Leonardo, Sireci, Francesca, Sola, Patrizia, Solaro, Claudio, Sotgiu, Stefano, Sparaco, Maddalena, Stromillo, Maria Laura, Strumia, Silvia, Susani, Emanuela Laura, Tabiadon, Giulietta, Teatini, Francesco, Tomassini, Valentina, Tonietti, Simone, Torri, Clerici Valentina, Tortorella, Carla, Toscano, Simona, Totaro, Rocco, Trotta, Maria, Turano, Gabriella, Ulivelli, Monica, Valentino, Manzo, Vaula, Giovanna, Vecchio, Domizia, Vercellino, Marco, Verrengia, Elena Pinuccia, Vianello, Marika, Virgilio, Eleonora, Vitetta, Francesca, Vollaro, Stefano, Zaffaroni, Mauro, Zampolini, Mauro, Zarbo, Ignazio Roberto, and Zuliani, Luigi

Published
2022
Full Text
View/download PDF

7. Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis.

Author

Simula, Elena Rita, Zarbo, Ignazio Roberto, Arru, Giannina, Sechi, Elia, Meloni, Rossella, Deiana, Giovanni Andrea, Solla, Paolo, and Sechi, Leonardo Antonio

Subjects
*MYASTHENIA gravis, *AUTOANTIBODIES, *ANTIBODY formation, *HUMAN endogenous retroviruses, *EPITOPES, *MUSCLE weakness, *ENZYME-linked immunosorbent assay
Abstract

Myasthenia gravis is an antibody-mediated autoimmune neurological disorder characterized by impaired neuromuscular junction transmission, resulting in muscle weakness. Recently, the involvement of Human Endogenous Retroviruses (HERVs) in the pathophysiology of different immune-mediated and neurodegenerative diseases, such as multiple sclerosis, has been demonstrated. We aimed to investigate potential immune system involvement related to humoral responses targeting specific epitopes of HERV-K and HERV-W envelope proteins in myasthenia gravis. Myasthenia gravis patients were recruited in the Neurology Unit, while healthy controls were selected from the Blood Transfusion Center, both affiliated with AOU Sassari. Highly immunogenic antigens of HERV-K and HERV-W envelope proteins were identified using the Immune Epitope Database (IEDB) online tool. These epitopes were utilized in enzyme-linked immunosorbent assays (ELISA) to detect autoantibodies in serum directed against these sequences. The study involved 39 Healthy Donors and 47 MG patients, further categorized into subgroups based on the presence of autoantibodies: MG-AchR Ab+ (n = 17), MG-MuSK Ab+ (n = 7), double seronegative patients (MG-DSN, n = 18), MG-LRP4 Ab + (n = 4), and one patient with no antibodies data (n = 1). Our findings revealed high levels of autoantibodies in myasthenia gravis patients directed against the HERV-K-env-su(19–37), HERV-K-env-su(109–126), HERV-K-env-su(164–186), HERV-W-env(93–108), HERV-W-env(129–14), and HERV-W-env(248–262) epitopes. Notably, these results remained highly significant even when patients were subdivided into MG-AchR Ab+ and MG-DSN subgroups. Correlation analysis further revealed significant positive associations between the antibody levels against HERV-K and HERV-W families in patients, suggesting a synergistic action of the two HERVs in the pathology context since this correlation is absent in the control group. This study marks the first identification of a specific humoral response directed against defined epitopes of HERV-K and HERV-W envelope proteins in myasthenia gravis patients. These findings lay the foundation for future investigations aimed at elucidating the molecular mechanisms driving this immune response. The detection of these autoantibodies suggests the potential for novel biomarkers, especially within the MG-DSN patient subgroup, addressing the need for new biomarkers in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Published
2020
Full Text
View/download PDF

11. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

Author

Laroni, Alice, Signori, Alessio, Maniscalco, Giorgia T., Lanzillo, Roberta, Russo, Cinzia Valeria, Binello, Eleonora, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Bonavita, Simona, Clerico, Marinella, Baroncini, Damiano, Prosperini, Luca, La Gioia, Sara, Rossi, Silvia, Cocco, Eleonora, Frau, Jessica, Torri Clerici, Valentina, Signoriello, Elisabetta, Sartori, Arianna, Zarbo, Ignazio Roberto, Rasia, Sarah, Cordioli, Cinzia, Cerqua, Raffaella, Di Sapio, Alessia, Lavorgna, Luigi, Pontecorvo, Simona, Barrilà, Caterina, Saccà, Francesco, Frigeni, Barbara, Esposito, Sabrina, Ippolito, Domenico, Gallo, Fabio, and Sormani, Maria Pia

Published
2017
Full Text
View/download PDF

12. Effect of contralateral strength training on muscle weakness in people with multiple sclerosis: proof-of-concept case series

Author

Manca, Andrea, Cabboi, Maria Paola, Ortu, Enzo, Ginatempo, Francesca, Dragone, Daniele, Zarbo, Ignazio Roberto, de Natale, Edoardo Rosario, Mureddu, Giovanni, Bua, Guido, and Deriu, Franca

Subjects
Multiple sclerosis -- Research -- Care and treatment, Therapeutics, Physiological -- Health aspects -- Research, Physical therapy -- Health aspects -- Research, Muscle weakness -- Research -- Care and treatment, Health
Abstract

Background. The contralateral strength training (CST) effect is a transfer of muscle performance to the untrained limb following training of the contralateral side. Objective. The aim of this study was to explore, in individuals with multiple sclerosis (MS) presenting marked lower limb strength asymmetry, the effectiveness of CST on management of muscle weakness of the more-affected limb following training of the less-affected limb. Design. A single-subject research design was used. Methods. Eight individuals with MS underwent 16 to 18 high-intensity training sessions of the less-affected ankle dorsiflexor muscles. The primary outcome measure of this single-system case series was maximal strength expressed as peak moment and maximal work. Secondary outcome measures were: Six-Minute-Walk Test, Timed 'Up & Go' Test, 10-Meter Timed Walk Test, and Multiple Sclerosis Quality of Life-54 questionnaire. Results. After the 6-week intervention, the contralateral more affected (untrained) limb showed a 22% to 24% increase in maximal strength. From pretest-posttest measurements, participants also performed significantly better on the clinical and functional secondary outcome measures. At the 12-week follow-up, the strength levels of the weaker untrained limb remained significantly superior to baseline levels in the majority (5 out of 8) of the outcome parameters. Limitations. Considering the design used, the absence of a control group, and the sample size, these findings should be cautiously generalized and will need confirmation in a properly planned randomized controlled trial. Conclusions. The present proof-of-concept study shows, for the first time, the occurrence of the CST effect on muscle performance of ankle dorsiflexor muscles in people with MS. These preliminary findings reveal new potential implications for CST as a promising rehabilitation approach to those conditions where unilateral muscle weakness does not allow or makes difficult performing conventional strength training of the weaker limb., Multiple sclerosis (MS) is a neurological condition characterized by reduced muscle strength during both dynamic and static muscle contractions. (1) Compared with matched healthy people, people with MS present a [...]

Published
2016
Full Text
View/download PDF

13. Rasagiline Withdrawal Syndrome in Parkinson’s Disease

Author

Solla, Paolo, primary, Ercoli, Tommaso, additional, Masala, Carla, additional, Orofino, Gianni, additional, Fadda, Laura, additional, Corda, Davide Giacomo, additional, Zarbo, Ignazio Roberto, additional, Meloni, Mario, additional, Sechi, Elia, additional, Bagella, Caterina Francesca, additional, and Defazio, Giovanni, additional

Published
2022
Full Text
View/download PDF

14. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

Author

Pitzalis, Maristella, primary, Idda, Maria Laura, additional, Lodde, Valeria, additional, Loizedda, Annalisa, additional, Lobina, Monia, additional, Zoledziewska, Magdalena, additional, Virdis, Francesca, additional, Delogu, Giuseppe, additional, Pirinu, Federica, additional, Marini, Maria Giuseppina, additional, Mingoia, Maura, additional, Frau, Jessica, additional, Lorefice, Lorena, additional, Fronza, Marzia, additional, Carmagnini, Daniele, additional, Carta, Elisa, additional, Orrù, Valeria, additional, Uzzau, Sergio, additional, Solla, Paolo, additional, Loi, Federica, additional, Devoto, Marcella, additional, Steri, Maristella, additional, Fiorillo, Edoardo, additional, Floris, Matteo, additional, Zarbo, Ignazio Roberto, additional, Cocco, Eleonora, additional, and Cucca, Francesco, additional

Published
2021
Full Text
View/download PDF

16. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Author

Sormani, Maria Pia, primary, Schiavetti, Irene, additional, Landi, Doriana, additional, Carmisciano, Luca, additional, De Rossi, Nicola, additional, Cordioli, Cinzia, additional, Moiola, Lucia, additional, Radaelli, Marta, additional, Immovilli, Paolo, additional, Capobianco, Marco, additional, Brescia Morra, Vincenzo, additional, Trojano, Maria, additional, Tedeschi, Gioacchino, additional, Comi, Giancarlo, additional, Battaglia, Mario Alberto, additional, Patti, Francesco, additional, Fragoso, Yara Dadalti, additional, Sen, Sedat, additional, Siva, Aksel, additional, Furlan, Roberto, additional, Salvetti, Marco, additional, Abbadessa, Gianmarco, additional, Aguglia, Umberto, additional, Allegorico, Lia, additional, Allegri, Rossi Beatrice Maria, additional, Amato, Maria Pia, additional, Annovazzi, Pietro, additional, Antozzi, Carlo, additional, Appendino, Lucia, additional, Arena, Sebastiano, additional, Baione, Viola, additional, Balgera, Roberto, additional, Barcella, Valeria, additional, Baroncini, Damiano, additional, Barrilà, Caterina, additional, Battaglia, Mario A., additional, Bellacosa, Alessandra, additional, Bellucci, Gianmarco, additional, Bergamaschi, Roberto, additional, Bergamaschi, Valeria, additional, Bezzini, Daiana, additional, Biolzi, Beatrice, additional, Bisecco, Alvino, additional, Bonavita, Simona, additional, Borriello, Giovanna, additional, Bosa, Chiara, additional, Bosco, Antonio, additional, Bovis, Francesca, additional, Bozzali, Marco, additional, Brambilla, Laura, additional, Brescia, Morra Vincenzo, additional, Brichetto, Giampaolo, additional, Buccafusca, Maria, additional, Bucciantini, Elisabetta, additional, Bucello, Sebastiano, additional, Buscarinu, Maria Chiara, additional, Cabboi, Maria Paola, additional, Calabrese, Massimiliano, additional, Calabria, Francesca, additional, Caleri, Francesca, additional, Camilli, Federico, additional, Caniatti, Luisa Maria, additional, Cantello, Roberto, additional, Capra, Ruggero, additional, Capuano, Rocco, additional, Carta, Patrizia, additional, Cavalla, Paola, additional, Celani, Maria Grazia, additional, Cellerino, Maria, additional, Cerqua, Raffaella, additional, Chisari, Clara, additional, Clerici, Raffaella, additional, Clerico, Marinella, additional, Cocco, Eleonora, additional, Cola, Gaia, additional, Confalonieri, Paolo, additional, Conte, Antonella, additional, Conti, Marta Zaffira, additional, Cordano, Christian, additional, Cordera, Susanna, additional, Corea, Francesco, additional, Correale, Claudio, additional, Cottone, Salvatore, additional, Crescenzo, Francesco, additional, Curti, Erica, additional, d’Ambrosio, Alessandro, additional, D’Amico, Emanuele, additional, Danni, Maura Chiara, additional, d’Arma, Alessia, additional, Dattola, Vincenzo, additional, de Biase, Stefano, additional, De Luca, Giovanna, additional, De Mercanti, Stefania Federica, additional, De Mitri, Paolo, additional, De Stefano, Nicola, additional, Della Cava, Marco, additional, di Napoli, Mario, additional, Di Sapio, Alessia, additional, Docimo, Renato, additional, Dutto, Anna, additional, Evangelista, Luana, additional, Fanara, Salvatore, additional, Ferraro, Diana, additional, Ferrò, Maria Teresa, additional, Filippi, Massimo, additional, Fioretti, Cristina, additional, Fratta, Mario, additional, Frau, Jessica, additional, Fronza, Marzia, additional, Gajofatto, Alberto, additional, Gallo, Antonio, additional, Gallo, Paolo, additional, Gasperini, Claudio, additional, Ghazaryan, Anna, additional, Giometto, Bruno, additional, Gobbin, Francesca, additional, Govone, Flora, additional, Granella, Franco, additional, Grange, Erica, additional, Grasso, Maria Grazia, additional, Guareschi, Angelica, additional, Guaschino, Clara, additional, Guerrieri, Simone, additional, Guidetti, Donata, additional, Iaffaldano, Pietro, additional, Ianniello, Antonio, additional, Iasevoli, Luigi, additional, Imperiale, Daniele, additional, Infante, Maria Teresa, additional, Inglese, Matilde, additional, Iodice, Rosa, additional, Iovino, Aniello, additional, Konrad, Giovanna, additional, Lanzillo, Roberta, additional, Lapucci, Caterina, additional, Lavorgna, Luigi, additional, L’Episcopo Maria, Rita, additional, Leva, Serena, additional, Liberatore, Giuseppe, additional, Lo Re, Marianna, additional, Longoni, Marco, additional, Lopiano, Leonardo, additional, Lorefice, Lorena, additional, Lucchini, Matteo, additional, Lus, Giacomo, additional, Maimone, Davide, additional, Malentacchi, Maria, additional, Mallucci, Giulia, additional, Malucchi, Simona, additional, Mancinelli, Chiara Rosa, additional, Mancinelli, Luca, additional, Manganotti, Paolo, additional, Maniscalco, Teresa Giorgia, additional, Mantero, Vittorio, additional, Marangoni, Sabrina, additional, Marastoni, Damiano, additional, Marfia, Alessandra Girolama, additional, Marinelli, Fabiana, additional, Marti, Alessandro, additional, Martinelli Boneschi, Filippo, additional, Masserano Zoli, Federco, additional, Matta, Francesca, additional, Mendozzi, Laura, additional, Meucci, Giuseppe, additional, Miante, Silvia, additional, Miele, Giuseppina, additional, Milano, Eva, additional, Mirabella, Massimiliano, additional, Missione, Rosanna, additional, Moccia, Marcello, additional, Montepietra, Sara, additional, Monti Bragadin, Margherita, additional, Montini, Federico, additional, Motta, Roberta, additional, Nardone, Raffaele, additional, Nicoletti, Carolina Gabri, additional, Nobile-Orazio, Eduardo, additional, Nozzolillo, Agostino, additional, Onofrj, Marco, additional, Orlandi, Riccardo, additional, Palmieri, Anna, additional, Paolicelli, Damiano, additional, Pasquali, Livia, additional, Pastò, Luisa, additional, Pedrazzoli, Elisabetta, additional, Perini, Paola, additional, Pesci, Ilaria, additional, Petracca, Maria, additional, Petrone, Alfredo, additional, Piantadosi, Carlo, additional, Pietroboni, Anna M., additional, Pinardi, Federica, additional, Ponzano, Marta, additional, Portaccio, Emilio, additional, Pozzato, Mattia, additional, Pozzilli, Carlo, additional, Prosperini, Luca, additional, Protti, Alessandra, additional, Ragonese, Paolo, additional, Rasia, Sarah, additional, Realmuto, Sabrina, additional, Repice, Anna, additional, Rigoni, Eleonora, additional, Rilla, Maria Teresa, additional, Rinaldi, Francesca, additional, Romano, Calogero Marcello, additional, Ronzoni, Marco, additional, Rovaris, Marco, additional, Ruscica, Francesca, additional, Sabattini, Loredana, additional, Salemi, Giuseppe, additional, Saraceno, Lorenzo, additional, Sartori, Alessia, additional, Sartori, Arianna, additional, Sbragia, Elvira, additional, Scandellari, Cinzia, additional, Scarano Giuditta, Ilaria, additional, Scarano, Valentina, additional, Schillaci, Valentina, additional, Sessa, Maria, additional, Sgarito, Caterina, additional, Sibilia, Grazia, additional, Siciliano, Gabriele, additional, Signori, Alessio, additional, Signoriello, Elisabetta, additional, Sinisi, Leonardo, additional, Sireci, Francesca, additional, Sola, Patrizia, additional, Solaro, Claudio, additional, Sormani, Maria Pia, additional, Sotgiu, Stefano, additional, Sparaco, Maddalena, additional, Stromillo, Maria Laura, additional, Strumia, Silvia, additional, Susani, Laura Emanuela, additional, Tabiadon, Giulietta, additional, Teatini, Francesco, additional, Tomassini, Valentina, additional, Tonietti, Simone, additional, Torri, Clerici Valentina, additional, Tortorella, Carla, additional, Toscano, Simona, additional, Totaro, Rocco, additional, Trotta, Maria, additional, Turano, Gabriella, additional, Ulivelli, Monica, additional, Valentino, Manzo, additional, Vaula, Giovanna, additional, Vecchio, Domizia, additional, Vercellino, Marco, additional, Verrengia, Elena Pinuccia, additional, Vianello, Marika, additional, Virgilio, Eleonora, additional, Vitetta, Francesca, additional, Vollaro, Stefano, additional, Zaffaroni, Mauro, additional, Zampolini, Mauro, additional, Zarbo, Ignazio Roberto, additional, Zito, Antonio, additional, and Zuliani, Luigi, additional

Published
2021
Full Text
View/download PDF

18. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Author

Maniscalco, Giorgia T., primary, Saccà, Francesco, additional, Lanzillo, Roberta, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Binello, Eleonora, additional, Repice, Annamaria, additional, Perini, Paola, additional, Clerico, Marinella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, La Gioia, Sara, additional, Gutierrez, Lorena Pareja, additional, Laroni, Alice, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Torri Clerici, Valentina, additional, Zarbo, Ignazio Roberto, additional, Sartori, Arianna, additional, Signoriello, Elisabetta, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Stromillo, Maria Laura, additional, Cerqua, Raffaella, additional, Pontecorvo, Simona, additional, Di Sapio, Alessia, additional, Grasso, Roberta, additional, Barone, Stefania, additional, Lavorgna, Luigi, additional, Barrilà, Caterina, additional, Landi, Doriana, additional, Russo, Cinzia Valeria, additional, Frigeni, Barbara, additional, Ippolito, Domenico, additional, Turano, Gabriella, additional, Carmisciano, Luca, additional, Sormani, Maria Pia, additional, and Signori, Alessio, additional

Published
2020
Full Text
View/download PDF

19. MSJ790390_supplementary_material – Supplemental material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Saccà, Francesco, Lanzillo, Roberta, Signori, Alessio, Maniscalco, Giorgia T, Signoriello, Elisabetta, Fermo, Salvatore Lo, Repice, Annamaria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Rossi, Silvia, Gutierrez, Lorena Pareja, Gioia, Sara La, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Sapio, Alessia Di, Pontecorvo, Simona, Grasso, Roberta, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Bovis, Francesca, Gallo, Fabio, and Sormani, Maria Pia

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, MSJ790390_supplementary_material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study by Francesco Saccà, Roberta Lanzillo, Alessio Signori, Giorgia T Maniscalco, Elisabetta Signoriello, Salvatore Lo Fermo, Annamaria Repice, Pietro Annovazzi, Damiano Baroncini, Marinella Clerico, Eleonora Binello, Raffaella Cerqua, Giorgia Mataluni, Simona Bonavita, Luigi Lavorgna, Ignazio Roberto Zarbo, Alice Laroni, Silvia Rossi, Lorena Pareja Gutierrez, Sara La Gioia, Barbara Frigeni, Valeria Barcella, Jessica Frau, Eleonora Cocco, Giuseppe Fenu, Valentina Torri Clerici, Arianna Sartori, Sarah Rasia, Cinzia Cordioli, Alessia Di Sapio, Simona Pontecorvo, Roberta Grasso, Caterina Barrilà, Cinzia Valeria Russo, Sabrina Esposito, Domenico Ippolito, Francesca Bovis, Fabio Gallo and Maria Pia Sormani in Multiple Sclerosis Journal

Published
2018
Full Text
View/download PDF

21. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Saccà, Francesco, primary, Lanzillo, Roberta, additional, Signori, Alessio, additional, Maniscalco, Giorgia T, additional, Signoriello, Elisabetta, additional, Lo Fermo, Salvatore, additional, Repice, Annamaria, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Clerico, Marinella, additional, Binello, Eleonora, additional, Cerqua, Raffaella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, Lavorgna, Luigi, additional, Zarbo, Ignazio Roberto, additional, Laroni, Alice, additional, Rossi, Silvia, additional, Pareja Gutierrez, Lorena, additional, La Gioia, Sara, additional, Frigeni, Barbara, additional, Barcella, Valeria, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Fenu, Giuseppe, additional, Torri Clerici, Valentina, additional, Sartori, Arianna, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Di Sapio, Alessia, additional, Pontecorvo, Simona, additional, Grasso, Roberta, additional, Barrilà, Caterina, additional, Russo, Cinzia Valeria, additional, Esposito, Sabrina, additional, Ippolito, Domenico, additional, Bovis, Francesca, additional, Gallo, Fabio, additional, and Sormani, Maria Pia, additional

Published
2018
Full Text
View/download PDF

22. Influence of psychological and social factors on self perceived health-related quality of life in patients with multiple sclerosis

Author

Zarbo, Ignazio Roberto and Pugliatti, Maura

Subjects
humanities, MED/26 Neurologia
Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, affecting people of young age and often leading to disability. Self-perceived health-related quality of life (HRQoL) is reduced in MS patients. Aims: This study aims to investigate the impact of psychological variables on the HRQoL of patients suffering from MS. Methods: Two-hundred-fifty patients with diagnosis of MS according to universally recognized criteria were consecutively recruited and underwent neurological examination with EDSS score and interviewed for past and current medical history. Patients were administered the Cognitive Behavioral Assessment (CBA) primary scales, aimed to assess a broad spectrum of psychological aspects. HRQoL was assessed by means a generic scale, the SF-36. Results: We found an association between MS patients’ HRQoL and specific psychological variables, mainly personality traits, such as extroversion and neuroticism (p Conclusions: As a patient-reported outcome, HRQoL in MS patients is likely to be influenced by individual psychological traits. Our study suggests that self-perception of HRQoL depends, among other determinants, on specific psychological variables. This association appears to be partly independent of degree of disability.

Published
2016

23. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Author

Saccà, Francesco, Lanzillo, Roberta, Signori, Alessio, Maniscalco, Giorgia T, Signoriello, Elisabetta, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Rossi, Silvia, Pareja Gutierrez, Lorena, and La Gioia, Sara

Subjects
MULTIPLE sclerosis, MULTIPLE sclerosis treatment, DECISION making
Abstract

Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy choice. Methods: Newly diagnosed relapsing–remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, and magnetic resonance imaging (MRI) data to the switch probability for lack of efficacy or intolerance/safety with a multivariate Cox analysis and estimated switch rates by competing risks models. Results: We enrolled 3025 patients. The overall switch frequency was 48% after 3 years. Switch risk for lack of efficacy was lower with fingolimod (hazard ratio (HR) = 0.50; p = 0.009), natalizumab (HR = 0.13; p < 0.001), dimethyl-fumarate (HR = 0.60; p = 0.037), teriflunomide (HR = 0.21; p = 0.031) as compared to interferons. Younger age (HR = 0.96; p < 0.001), diagnosis delay (HR = 1.23; p = 0.021), higher baseline Expanded Disability Status Scale (HR = 1.17; p = 0.001), and spinal cord lesions (HR = 1.46; p = 0.001) were independently associated with higher inefficacy switch rates. We found lower switch for intolerance/safety with glatiramer acetate (HR = 0.61; p = 0.001), fingolimod (HR = 0.35; p = 0.002), and dimethyl-fumarate (HR = 0.57; p = 0.022) as compared to interferons, while it increased with natalizumab (HR = 1.43; p = 0.022). Comorbidities were associated with intolerance switch (HR = 1.28; p = 0.047). Conclusion: Several factors are associated with higher switch risk in patients starting a first-line therapy and could be integrated in the decision-making process of first treatment choice. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

25. Switch Strategies in RRMS: A Real-Life Multi Center Study (S24.003)

Author

Sacc, Francesco, primary, Signori, Alessio, additional, Maniscalco, Giorgia Teresa, additional, Lanzillo, Roberta, additional, Lo Fermo, Salvatore, additional, Annovazzi, Pietro, additional, Prosperini, Luca, additional, Cocco, Eleonora, additional, Bonavita, Simona, additional, Torri Clerici, Valentina, additional, Laroni, Alice, additional, Repice, Anna Maria, additional, Zarbo, Ignazio Roberto, additional, Raffaella, Cerqua, additional, Di Sapio, Alessia, additional, Pontecorvo, Simona, additional, Clerico, Marinella, additional, Lavorgna, Luigi, additional, Barrillà, Caterina, additional, Cordioli, Cinzia, additional, Gallo, Fabio, additional, and Sormani, Maria Pia, additional

Published
2016
Full Text
View/download PDF

27. An innovative training program based on virtual reality and treadmill: effects on gait of persons with multiple sclerosis.

Author

Peruzzi, Agnese, Zarbo, Ignazio Roberto, Cereatti, Andrea, Della Croce, Ugo, and Mirelman, Anat

Subjects
*PHYSICAL fitness, *TREATMENT effectiveness, *ANALYSIS of variance, *CONFIDENCE intervals, *DIAGNOSIS, *DYNAMICS, *POSTURAL balance, *GAIT in humans, *RANGE of motion of joints, *KINEMATICS, *MULTIPLE sclerosis, *RESEARCH funding, *STATISTICAL sampling, *T-test (Statistics), *VIRTUAL reality, *PILOT projects, *TREADMILLS, *RANDOMIZED controlled trials, *REPEATED measures design, *BLIND experiment, GAIT disorder treatment
Abstract

Aim:In this single blind randomized controlled trial, we examined the effect of a virtual reality-based training on gait of people with multiple sclerosis. Methods:Twenty-five individuals with multiple sclerosis with mild to moderate disability were randomly assigned to either the control group (n = 11) or the experimental group (n = 14). The subjects in the control group received treadmill training. Subjects in the experimental group received virtual reality based treadmill training. Clinical measures and gait parameters were evaluated. Result:Subjects in both the groups significantly improved the walking endurance and speed, cadence and stride length, lower limb joint ranges of motion and powers, during single and dual task gait. Moreover, subjects in the experimental group also improved balance, as indicated by the results of the clinical motor tests (p < 0.05). Between-group comparisons revealed that the experimental group improved significantly more than control group in hip range of motion and hip generated power at terminal stance at post-training. Conclusion:Our results support the perceived benefits of training programs that incorporate virtual reality to improve gait measures in individuals with multiple sclerosis. Implication of rehabilitationGait deficits are common in multiple sclerosis (85%) and worsen during dual task activities.Intensive and progressive treadmill training, with and without virtual reality, is effective on dual task gait in persons with multiple sclerosis.Virtual reality-based treadmill training requiring obstacle negotiation increases the range of motion and the power generated at the hip, consequently allowing longer stride length and, consequently, higher gait speed. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

28. Personality traits predict perceived health-related quality of life in persons with multiple sclerosis.

Author

Zarbo, Ignazio Roberto, Minacapelli, Eleonora, Falautano, Monica, Demontis, Silvia, Carpentras, Giovanni, and Pugliatti, Maura

Subjects
*QUALITY of life, *MULTIPLE sclerosis, *NEUROBEHAVIORAL disorders, *ANALYSIS of variance, *NEUROTICISM, *EXTRAVERSION, *PATIENTS
Abstract

Background: Personality traits can affect health-related quality of life (HRQoL) in different disorders. In multiple sclerosis (MS), personality traits can determine patients’ willingness to take on more risky treatment options, predispose to neuropsychiatric symptoms and affect coping strategies. Objectives: We investigated the role of personality traits as possible predictors of HRQoL in a large cohort of persons with MS (PwMS). Methods: In total, 253 consecutively recruited PwMS were screened for intellectual deficits with Raven Colour Progressive Matrices (RCPM), state anxiety with STAI-X1 and major depression on a clinical basis. PwMS’ self-perceived mental and physical health status was measured with the 36-Item Short Form Health Survey (SF-36), and the personality profile with the Eysenck Personality Questionnaire (EPQ-R). The correlation between HRQoL and personality traits was investigated by means of analysis of variance, adjusting for possible confounders. Results: Of the 253 MS patients, 195 (F:M=2.75), aged 41.7±10.2 years were included in the analysis. The variance of SF-36 mental and physical composite score was largely explained by extraversion and neuroticism. Conclusions: Our data confirm that PwMS’ HRQoL is largely influenced by personality traits, which may therefore act as predictors of perceived quality of life and should be included in clinical and experimental settings focusing on HRQoL. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

29. Switch Strategies in RRMS: A Real-Life Multi Center Study

Author

Sacc, Francesco, Signori, Alessio, Maniscalco, Giorgia Teresa, Lanzillo, Roberta, Lo Fermo, Salvatore, Annovazzi, Pietro, Prosperini, Luca, Cocco, Eleonora, Bonavita, Simona, Clerici, Valentina Torri, Laroni, Alice, Repice, Anna Maria, Zarbo, Ignazio Roberto, Raffaella, Cerqua, Di Sapio, Alessia, Pontecorvo, Simona, Marinella CLERICO, Lavorgna, Luigi, Barrilla, Caterina, Cordioli, Cinzia, Gallo, Fabio, and Sormani, Maria Pia

30. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Domenico Ippolito, Sara La Gioia, Sabrina Esposito, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Cinzia Cordioli, Lorena Pareja-Gutierrez, Elisabetta Signoriello, Cinzia Valeria Russo, Roberta Grasso, Doriana Landi, B. Frigeni, Andrea Visconti, Caterina Barrilà, Valeria Barcella, Raffaella Cerqua, Alice Laroni, Simona Bonavita, Stefania Barone, P. Perini, Sarah Rasia, Arianna Sartori, Maria Laura Stromillo, Roberta Lanzillo, Damiano Baroncini, Jessica Frau, Francesco Saccà, Luigi Lavorgna, Alessio Signori, Ignazio Roberto Zarbo, Giorgia Mataluni, Eleonora Cocco, Maria Pia Sormani, E Binello, Pietro Annovazzi, M Clerico, Simona Pontecorvo, Giuseppe Fenu, Alessia Di Sapio, Anna Maria Repice, Signori, A., Sacca, F., Lanzillo, R., Maniscalco, G. T., Signoriello, E., Repice, A. M., Annovazzi, P., Baroncini, D., Clerico, M., Binello, E., Cerqua, R., Mataluni, G., Perini, P., Bonavita, S., Lavorgna, L., Zarbo, I. R., Laroni, A., Pareja-Gutierrez, L., La Gioia, S., Frigeni, B., Barcella, V., Frau, J., Cocco, E., Fenu, G., Clerici, V. T., Sartori, A., Rasia, S., Cordioli, C., Stromillo, M. L., Di Sapio, A., Pontecorvo, S., Grasso, R., Barone, S., Barrila, C., Russo, C. V., Esposito, S., Ippolito, D., Landi, D., Visconti, A., Sormani, M. P., Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, Datasets as Topic, Settore MED/26, Placebo, Severity of Illness Index, law.invention, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Randomized controlled trial, law, Internal medicine, Outcome Assessment, Health Care, Severity of illness, medicine, Humans, Immunologic Factors, Multicenter Studies as Topic, Glatiramer acetate, Cladribine, Randomized Controlled Trials as Topic, Retrospective Studies, business.industry, Middle Aged, Fingolimod, Observational Studies as Topic, Neurology, Propensity score matching, Disease Progression, Female, Neurology (clinical), business, medicine.drug
Abstract

ObjectiveCladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to observational data.MethodsData from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity score matched to data from the Italian multicenter database i-MuST. This database included 3,150 patients diagnosed between 2010 and 2018 at 24 Italian MS centers who started a disease-modifying drug. The annualized relapse rate (ARR) over 2 years from treatment start and the 24-week confirmed disability progression were compared between patients treated with cladribine and other approved drugs (interferon, glatiramer acetate, fingolimod, natalizumab, and dimethyl fumarate), with comparisons with placebo as a reference. Treatment effects were estimated by the inverse probability weighting negative binomial regression model for ARR and Cox model for disability progression. The treatment effect has also been evaluated according to baseline disease activity.ResultsAll weighted baseline characteristics were well balanced between groups. All drugs tested had an effect vs placebo close to that detected in the RCT. Patients treated with cladribine had a significantly lower ARR compared with interferon (relapse ratio [RR] = 0.48; p < 0.001), glatiramer acetate (RR = 0.49; p < 0.001), and dimethyl fumarate (RR = 0.6; p = 0.001); a similar ARR to that with fingolimod (RR = 0.74; p = 0.24); and a significantly higher ARR than natalizumab (RR = 2.13; p = 0.014), confirming results obtained by indirect treatment comparisons from RCTs (network meta-analyses). The relative effect of cladribine tablets 10 mg (cumulative dose 3.5 mg/kg over 2 years) was higher in patients with high disease activity vs all treatments except fingolimod and natalizumab. Effects on disability progression were largely nonsignificant, probably due to lack of power for such analysis.ConclusionIn patients with RRMS, cladribine tablets showed lower ARR compared with matched patients who started interferon, glatiramer acetate, or dimethyl fumarate; was similar to fingolimod; and was higher than natalizumab. The beneficial effect of cladribine tablets was generally amplified in the subgroup of patients with high disease activity.Classification of evidenceThis study provides Class III evidence that for patients with RRMS, cladribine-treated patients had lower ARR compared with interferon, glatiramer acetate, or dimethyl fumarate; similar ARR compared with fingolimod; and higher ARR compared with natalizumab.

Published
2020

31. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Caterina Barrilà, Alice Laroni, Raffaella Cerqua, Giorgia Teresa Maniscalco, Alessia Di Sapio, Jessica Frau, Alessio Signori, A. Repice, Domenico Ippolito, Sara La Gioia, Giuseppe Fenu, Ignazio Roberto Zarbo, Francesco Saccà, Giorgia Mataluni, Sabrina Esposito, Elisabetta Signoriello, Arianna Sartori, Simona Bonavita, Eleonora Cocco, Roberta Lanzillo, Salvatore Lo Fermo, B. Frigeni, Valeria Barcella, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Sarah Rasia, Cinzia Cordioli, Roberta Grasso, Valentina Torri Clerici, Damiano Baroncini, Lorena Pareja Gutierrez, Luigi Lavorgna, Marinella Clerico, Cinzia Valeria Russo, Fabio Gallo, Francesca Bovis, Silvia Rossi, Saccà, Francesco, Lanzillo, Roberta, Signori, Alessio, Maniscalco, Giorgia T, Signoriello, Elisabetta, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Rossi, Silvia, Pareja Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Torri Clerici, Valentina, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Bovis, Francesca, Gallo, Fabio, and Sormani, Maria Pia

Subjects
Persistence (psychology), Adult, Male, medicine.medical_specialty, Pediatrics, Neurology, Adolescent, naïve, relapsing–remitting, Therapy naive, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, disease modifying therapies, Medicine, Humans, Immunologic Factors, 030212 general & internal medicine, real-life, Aged, Retrospective Studies, business.industry, Drug Substitution, Multiple sclerosis, Switch, persistence, Middle Aged, medicine.disease, Relapsing remitting, Italy, disease modifying therapies, naïve, persistence, real-life, relapsing–remitting, Switch, Neurology, Neurology (clinical), disease modifying therapie, Female, Neurology (clinical), business, Life study, 030217 neurology & neurosurgery
Abstract

Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy choice. Methods: Newly diagnosed relapsing–remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, and magnetic resonance imaging (MRI) data to the switch probability for lack of efficacy or intolerance/safety with a multivariate Cox analysis and estimated switch rates by competing risks models. Results: We enrolled 3025 patients. The overall switch frequency was 48% after 3 years. Switch risk for lack of efficacy was lower with fingolimod (hazard ratio (HR) = 0.50; p = 0.009), natalizumab (HR = 0.13; p Conclusion: Several factors are associated with higher switch risk in patients starting a first-line therapy and could be integrated in the decision-making process of first treatment choice.

Published
2019

32. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

Author

Alice, Laroni, Alessio, Signori, Giorgia T, Maniscalco, Roberta, Lanzillo, Cinzia Valeria, Russo, Eleonora, Binello, Salvatore, Lo Fermo, Annamaria, Repice, Pietro, Annovazzi, Simona, Bonavita, Marinella, Clerico, Damiano, Baroncini, Luca, Prosperini, Sara, La Gioia, Silvia, Rossi, Eleonora, Cocco, Jessica, Frau, Valentina, Torri Clerici, Elisabetta, Signoriello, Arianna, Sartori, Ignazio Roberto, Zarbo, Sarah, Rasia, Cinzia, Cordioli, Raffaella, Cerqua, Alessia, Di Sapio, Luigi, Lavorgna, Simona, Pontecorvo, Caterina, Barrilà, Francesco, Saccà, Barbara, Frigeni, Sabrina, Esposito, Domenico, Ippolito, Fabio, Gallo, Maria Pia, Sormani, Laroni, Alice, Signori, Alessio, Maniscalco, Giorgia T., Lanzillo, Roberta, Russo, Cinzia Valeria, Binello, Eleonora, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Bonavita, Simona, Clerico, Marinella, Baroncini, Damiano, Prosperini, Luca, La Gioia, Sara, Rossi, Silvia, Cocco, Eleonora, Frau, Jessica, Torri Clerici, Valentina, Signoriello, Elisabetta, Sartori, Arianna, Zarbo, Ignazio Roberto, Rasia, Sarah, Cordioli, Cinzia, Cerqua, Raffaella, Di Sapio, Alessia, Lavorgna, Luigi, Pontecorvo, Simona, Barrilà, Caterina, Saccà, Francesco, Frigeni, Barbara, Esposito, Sabrina, Ippolito, Domenico, Gallo, Fabio, Sormani, Maria Pia, Laroni, A, Signori, A, Maniscalco, Gt, Lanzillo, R, Russo, Cv, Binello, E, Lo Fermo, S, Repice, A, Annovazzi, P, Bonavita, S, Clerico, M, Baroncini, D, Prosperini, L, La Gioia, S, Rossi, S, Cocco, E, Frau, J, Torri Clerici, V, Signoriello, E, Sartori, A, Zarbo, Ir, Rasia, S, Cordioli, C, Cerqua, R, Di Sapio, A, Lavorgna, L, Pontecorvo, S, Barrilà, C, Saccà, F, Frigeni, B, Esposito, S, Ippolito, D, Gallo, F, and Sormani, Mp

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Cardiovascular Abnormalities, Cohort Studies, Comorbidity, Disability Evaluation, Female, Humans, Immunosuppressive Agents, Italy, Mental Disorders, Metabolic Diseases, Middle Aged, Nervous System Diseases, Severity of Illness Index, Drug Substitution, Neurology (clinical), Immunosuppressive Agent, 03 medical and health sciences, 0302 clinical medicine, Natalizumab, Internal medicine, Multiple Sclerosi, Severity of illness, medicine, Cardiovascular Abnormalitie, Glatiramer acetate, Nervous System Disease, business.industry, Odds ratio, medicine.disease, Fingolimod, Metabolic Disease, 030104 developmental biology, Cohort, Mental Disorder, Cohort Studie, business, 030217 neurology & neurosurgery, Human, Cohort study, medicine.drug
Abstract

Objective:To assess whether the presence of concomitant diseases at multiple sclerosis (MS) diagnosis is associated with the choice and the treatment persistence in an Italian MS cohort.Methods:We included newly diagnosed patients (2010–2016) followed in 20 MS centers and collected demographic and clinical data. We evaluated baseline factors related to the presence of comorbidities and the association between comorbidities and the clinical course of MS and the time to the first treatment switch.Results:The study cohort included 2,076 patients. Data on comorbidities were available for 1,877/2,076 patients (90.4%). A total of 449/1,877 (23.9%) patients had at least 1 comorbidity at MS diagnosis. Age at diagnosis (odds ratio 1.05, 95% confidence interval [CI] 1.04–1.06; p < 0.001) was the only baseline factor independently related to the presence of comorbidities. Comorbidities were not significantly associated with the choice of the first disease-modifying treatment, but were significantly associated with higher risk to switch from the first treatment due to intolerance (hazard ratio 1.42, CI 1.07–1.87; p = 0.014). Association of comorbidities with risk of switching for intolerance was significantly heterogeneous among treatments (interferon β, glatiramer acetate, natalizumab, or fingolimod; interaction test, p = 0.04).Conclusions:Comorbidities at diagnosis should be taken into account at the first treatment choice because they are associated with lower persistence on treatment.

Published
2017

33. Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies.

Author

Doneddu PE, Briani C, Cocito D, Manganelli F, Fabrizi GM, Matà S, Mazzeo A, Fazio R, Benedetti L, Luigetti M, Inghilleri M, Ruiu E, Siciliano G, Cosentino G, Marfia GA, Carpo M, Filosto M, Antonini G, Notturno F, Sotgiu S, Cucurachi L, Dell'Aquila C, Bianchi E, Rosso T, Giordano A, Fernandes M, Campagnolo M, Peci E, Spina E, Tagliapietra M, Sperti M, Gentile L, Strano C, Germano F, Romozzi M, Moret F, Zarbo IR, Viola DV, Vegezzi E, Mataluni G, Cotti-Piccinelli S, Leonardi L, Carta A, and Nobile-Orazio E

Subjects
Humans, COVID-19 Vaccines adverse effects, SARS-CoV-2, Cross-Over Studies, Vaccination adverse effects, Recurrence, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating diagnosis, COVID-19 prevention & control, Polyneuropathies
Abstract

Background and Purpose: The aim was to evaluate the risk of relapse after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and its safety and tolerability, in patients with chronic inflammatory neuropathies., Methods: In this multicenter, cohort and case-crossover study, the risk of relapse associated with SARS-CoV-2 vaccination was assessed by comparing the frequency of relapse in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) patients who underwent or did not undergo vaccination. Frequency of relapse in the 3 months prior to and after vaccination, and safety and tolerability of SARS-CoV-2 vaccination, were also assessed., Results: In all, 336 patients were included (278 CIDP, 58 MMN). Three hundred and seven (91%) patients underwent SARS-CoV-2 vaccination. Twenty-nine patients (9%) did not undergo vaccination. Mild and transient relapses were observed in 16 (5%) patients (13 CIDP, 3 MMN) after SARS-CoV-2 vaccination and in none of the patients who did not undergo vaccination (relative risk [RR] 3.21, 95% confidence interval [CI] 0.19-52.25). There was no increase in the specific risk of relapse associated with type of vaccine or diagnosis. Comparison with the 3-month control period preceding vaccination revealed an increased risk of relapse after vaccination (RR 4.00, 95% CI 1.35-11.82), which was restricted to CIDP patients (RR 3.25, 95% CI 1.07-9.84). The safety profile of SARS-CoV-2 vaccination was characterized by short-term, mild-to-moderate local and systemic adverse events., Conclusions: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in CIDP and MMN patients does not seem to be associated with an increased risk of relapse at the primary end-point, although a slightly increased risk in CIDP patients was found compared to the 3 months before vaccination., (© 2023 European Academy of Neurology.)

Published
2023
Full Text
View/download PDF

34. RNA-binding proteins in autoimmunity: From genetics to molecular biology.

Author

Lodde V, Floris M, Zoroddu E, Zarbo IR, and Idda ML

Subjects
Humans, RNA, RNA-Binding Proteins genetics, Molecular Biology, RNA, Messenger, Autoimmunity genetics, Autoimmune Diseases genetics
Abstract

Autoimmune diseases (ADs) are chronic pathologies generated by the loss of immune tolerance to the body's own cells and tissues. There is growing recognition that RNA-binding proteins (RBPs) critically govern immunity in healthy and pathological conditions by modulating gene expression post-transcriptionally at all levels: nuclear mRNA splicing and modification, export to the cytoplasm, as well as cytoplasmic mRNA transport, storage, editing, stability, and translation. Despite enormous efforts to identify new therapies for ADs, definitive solutions are not yet available in many instances. Recognizing that many ADs have a strong genetic component, we have explored connections between the molecular biology and the genetics of RBPs in ADs. Here, we review the genetics and molecular biology of RBPs in four major ADs, multiple sclerosis (MS), type 1 diabetes mellitus (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). We anticipate that gaining insights into the genetics and biology of ADs can facilitate the discovery of new therapies. This article is categorized under: RNA in Disease and Development > RNA in Disease., (© 2023 The Authors. WIREs RNA published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

35. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Author

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, and Sormani MP

Subjects
Adolescent, Adult, Aged, Drug Substitution, Female, Humans, Italy, Male, Middle Aged, Retrospective Studies, Young Adult, Immunologic Factors adverse effects, Immunologic Factors therapeutic use, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences., Objectives: To identify prognostic factors for early switch after first therapy choice., Methods: Newly diagnosed relapsing-remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, and magnetic resonance imaging (MRI) data to the switch probability for lack of efficacy or intolerance/safety with a multivariate Cox analysis and estimated switch rates by competing risks models., Results: We enrolled 3025 patients. The overall switch frequency was 48% after 3 years. Switch risk for lack of efficacy was lower with fingolimod (hazard ratio (HR) = 0.50; p  = 0.009), natalizumab (HR = 0.13; p  < 0.001), dimethyl-fumarate (HR = 0.60; p  = 0.037), teriflunomide (HR = 0.21; p  = 0.031) as compared to interferons. Younger age (HR = 0.96; p  < 0.001), diagnosis delay (HR = 1.23; p  = 0.021), higher baseline Expanded Disability Status Scale (HR = 1.17; p  = 0.001), and spinal cord lesions (HR = 1.46; p  = 0.001) were independently associated with higher inefficacy switch rates. We found lower switch for intolerance/safety with glatiramer acetate (HR = 0.61; p  = 0.001), fingolimod (HR = 0.35; p  = 0.002), and dimethyl-fumarate (HR = 0.57; p  = 0.022) as compared to interferons, while it increased with natalizumab (HR = 1.43; p  = 0.022). Comorbidities were associated with intolerance switch (HR = 1.28; p  = 0.047)., Conclusion: Several factors are associated with higher switch risk in patients starting a first-line therapy and could be integrated in the decision-making process of first treatment choice.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results